Valirx
VAL · AIM · Health Care · mcap £1.8m · 0.1p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 15 Sep 26 | Results | Half-year Results
HALF YEARLY REPORT FOR THE PERIOD ENDED 30 JUNE 2026 |
+0.0% |
| 10 Aug 26 | Cytolytix Patent Update
London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, is pleased to provide the following updates on its majority owned subsidiary Cytolytix Limited (" |
+0.0% | |
| 22 Jun 26 | Conclusion of Evaluation with University of Dundee
London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health provides the following update at the conclusion of the Evaluation Agreement with the University of |
−8.1% | |
| 22 Jun 26 | Final Results & Notice of AGM
London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, announces its audited results for the year ended 31 December 2025. |
−8.1% | |
| 02 Jun 26 | Conclusion of Evaluation with Stingray
London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health provides the following update at the conclusion of the Evaluation Agreement with Stingray Bio Limi |
−2.6% | |
| 01 Jun 26 | ValiRx Exercises Option on Evaluation Asset
London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health is pleased to provide the following update on its evaluation agreement with The Royal Institute fo |
+0.0% | |
| 27 May 26 | Cytolytix Patent Granted
London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health is pleased to provide the following updates on its majority owned subsidiary Cytolytix Limited ("C |
+2.6% | |
| 21 May 26 | Fundraise | Result of Oversubscribed WRAP Retail Offer
London, UK - ValiRx Plc (AIM: VAL), an innovative life sciences company focusing on early-stage cancer therapeutics and women's health, with a pipeline of assets including CLX001 and VAL201, is pleased to confirm, furthe |
+2.6% |
| 18 May 26 | Offer | WRAP Retail Offer for up to £150,000
London, UK - ValiRx Plc (AIM: VAL), an innovative life sciences company focusing on early-stage cancer therapeutics and women's health, with a pipeline of assets including CLX001 and VAL201, is pleased to announce a reta |
−2.5% |
| 15 May 26 | Fundraise | Fundraising of up to £1,155,000
for in-licensing, IP portfolio expansion, preclinical development and expansion of ValiRx Animal Health |
−17.0% |
| 26 Mar 26 | ValiRx Commercial Update Q1 2026
London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health is pleased to share a commercial update for Q1 2026 against the objectives and milestones for 2026 |
+1.6% | |
| 24 Mar 26 | ValiRx and TwinEdge to present Digital Twin data
ValiRx and TwinEdge to present Digital Twin data |
+5.1% | |
| 02 Mar 26 | ValiRx forms ValiRx Animal Health Ltd subsidiary
ValiRx sets up wholly owned Subsidiary ValiRx Animal Health LTD |
+1.5% | |
| 19 Jan 26 | Exercise of Warrants
ValiRx plc (the "Company") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health announces it has received notification for the exercise of warrants over 80,000 ordinary share |
+0.0% | |
| 09 Jan 26 | Evaluation and Transfer Agreement
The following amendment has been made to the 'New Evaluation and Material Transfer Agreement' announcement released on 9 January 2026 at 7:00 a.m. under RNS No 2552O. |
−4.9% | |
| 09 Jan 26 | New Evaluation and Material Transfer Agreement
ValiRx plc (the "Company") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health and The Royal Institute for the Advancement of Learning/McGill University ("McGill"), a Canadi |
−4.9% | |
| 20 Nov 25 | Result of GM & Issue of Equity
London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, announces that, further to the announcement on 4 November 2025, at the Company's General Meeting |
−2.1% | |
| 04 Nov 25 | Fundraise | Result of WRAP Retail Offer
ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, is pleased to confirm, further to the announcements made on 30 October 2025, the result of WRAP Retail Offer |
−2.0% |
| 30 Oct 25 | Offer | WRAP Retail Offer for up to £300,000
ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, is pleased to announce a retail offer via the Winterflood Retail Access Platform ("WRAP") to raise up to £300 |
−47.4% |
| 30 Oct 25 | Fundraise | Fundraising of up to £1,050,000
Conditional Placing of 183,695,400 Tranche 2 Placing Shares |
−47.4% |
| 14 Oct 25 | Inaphaea Commercial update
London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, is pleased to provide the following updates on its wholly owned subsidiary Inaphaea Limited ("In |
+0.0% |
Company filings. Not investment advice.